AbbVie Inc (ABBV)vsPrivia Health Group Inc (PRVA)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
PRVA
Privia Health Group Inc
$21.84
+0.05%
HEALTHCARE · Cap: $2.88B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2630% more annual revenue ($64.39B vs $2.36B). ABBV leads profitability with a 9.8% profit margin vs 1.2%. ABBV trades at a lower P/E of 80.6x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PRVA
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Intrinsic value data unavailable for PRVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 250.0% YoY
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
ROE of 0.0% — below average capital efficiency
1.2% margin — thin
Operating margin of 1.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 107.2x leaves little room for execution misses. Thin 1.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.80 — expect wider price swings.
PRVA is growing revenue faster at 21.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 50/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?